Skip to Content
Notice

Interim Definition and Elimination of Lot-by-Lot Release For Well-Characterized Therapeutic Recombinant DNA-Derived and Monoclonal Antibody Biotechnology Products

The full text of this document is currently only available in PDF format. Download PDF

Site Feedback